DarioHealth Announces CFO Transition
Rhea-AI Summary
DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.
Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.
Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.
Positive
- Incoming CFO brings strong healthcare finance experience and proven track record in capital raising
- Smooth leadership transition planned with retiring CFO staying on as advisor
- Company has successfully expanded from single to multi-condition digital health platform
Negative
- Loss of experienced CFO who led company through significant transformation period
News Market Reaction
On the day this news was published, DRIO declined 2.67%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity.
"It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished," said Mr. Ben-David. "I am confident in Chen's ability to lead the Company's financial strategy and contribute to its continued growth."
Mrs. Franco-Yehuda brings extensive financial leadership experience, with a strong background in corporate finance, capital markets, and strategic growth initiatives. She has held senior financial leadership roles across publicly traded companies in the healthcare and life sciences sectors. Combining deep knowledge of healthcare business models with a sharp understanding of capital markets, her experience uniquely positions her to lead Dario's financial organization through its next phase of growth and expansion.
Prior to joining Dario, she most recently served as Chief Financial Officer, Treasurer, and Secretary at Pluri Inc. (Nasdaq, TASE: PLUR), a global biotech company, where she led financial strategy, investor relations, legal affairs, and significant cross-border transactions. She played an instrumental role in securing substantial capital through multiple public and private fundraising rounds, executing non-dilutive funding agreements and driving merger and acquisition activity. In recognition of her accomplishments, she was awarded the Israeli CFO Excellence Award in January 2025.
Chen's early career started as Audit/Assurance Manager at PwC. She is a licensed CPA in
"On behalf of the Board and the entire team at DarioHealth, I would like to express our gratitude to Zvi for his dedication and contributions to the Company," said Erez Raphael, CEO of DarioHealth. "During his tenure, Zvi played a key role in the Company's transformation from a single-condition solution provider into one of the most comprehensive multi-condition digital health platforms in the industry. His financial stewardship supported our strategic expansion across diabetes, hypertension, mental health, weight management, and musculoskeletal care, helping to position Dario as a leader in digital health. We look forward to welcoming Chen and leveraging her expertise as we continue to drive innovation and growth."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. . Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-announces-cfo-transition-302433262.html
SOURCE DarioHealth Corp.
FAQ
When will Chen Franco-Yehuda start as DarioHealth's (DRIO) new CFO?
What experience does DarioHealth's (DRIO) new CFO bring to the company?
How has DarioHealth (DRIO) expanded its services under the departing CFO's tenure?
What transition arrangements are in place for DarioHealth's (DRIO) CFO change?
